Published in Pediatr Blood Cancer on September 01, 2007
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients | NCT01239901
Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion (2013) 1.43
Living with iron (and oxygen): questions and answers about iron homeostasis. Chem Rev (2009) 1.24
Non-transfusion-dependent thalassemias. Haematologica (2013) 1.21
β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14
Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol (2013) 1.03
Erythrocytapheresis: Do Not Forget a Useful Therapy! Transfus Med Hemother (2008) 0.92
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90
Thalassaemia intermedia: an update. Mediterr J Hematol Infect Dis (2009) 0.88
Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements. Haematologica (2008) 0.86
Relationship Between Serum Hepcidin and Ferritin Levels in Patients With Thalassemia Major and Intermedia in Southern Iran. Iran Red Crescent Med J (2015) 0.84
Hemoglobin H-constant spring in North America: an alpha thalassemia with frequent complications. Am J Hematol (2009) 0.77
Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment. Biomed Res Int (2015) 0.76
Serum Ferritin Levels Correlation With Heart and Liver MRI and LIC in Patients With Transfusion-Dependent Thalassemia. Iran Red Crescent Med J (2015) 0.75
Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Br J Haematol (2016) 0.75
Dual-energy X-ray absorptiometry with serum ferritin predicts liver iron concentration and changes in concentration better than ferritin alone. J Clin Densitom (2010) 0.75
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther (2015) 0.75
MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. Pediatr Blood Cancer (2015) 0.75
Increased mitochondrial DNA deletions and copy number in transfusion-dependent thalassemia. JCI Insight (2016) 0.75
Serum ferritin in thalassemia intermedia. Indian J Hematol Blood Transfus (2013) 0.75
Unusual pattern in haemoglobin electrophoresis in Croatian population: a case report. Biochem Med (Zagreb) (2016) 0.75
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Brown adipose tissue activity controls triglyceride clearance. Nat Med (2011) 6.76
Pulmonary complications of sickle cell disease. N Engl J Med (2008) 4.11
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med (2006) 4.04
Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics (2008) 2.61
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev (2015) 2.11
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr (2003) 2.00
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol (2006) 1.99
Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med (2011) 1.89
Mucopolysaccharidosis VI. Orphanet J Rare Dis (2010) 1.87
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood (2004) 1.66
Management guidelines for mucopolysaccharidosis VI. Pediatrics (2007) 1.61
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis (2014) 1.60
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A (2005) 1.58
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am J Hematol (2009) 1.48
Temporary esophageal stenting allows healing of esophageal perforations following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol (2006) 1.44
Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol (2005) 1.41
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood (2010) 1.41
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol (2007) 1.39
Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat (2007) 1.30
The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr (2011) 1.27
Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. J Pain Symptom Manage (2002) 1.27
Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr (2009) 1.27
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica (2008) 1.26
Assessment of resident surgical skills: is testing feasible? Am J Obstet Gynecol (2005) 1.25
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Gene interactions and stroke risk in children with sickle cell anemia. Blood (2003) 1.23
Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr Hematol Oncol (2002) 1.22
Non-transfusion-dependent thalassemias. Haematologica (2013) 1.21
International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A (2014) 1.19
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica (2008) 1.18
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci (2009) 1.17
Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol (2009) 1.15
The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med (2008) 1.15
Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer (2009) 1.15
Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis (2013) 1.14
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci (2005) 1.14
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One (2013) 1.14
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol (2003) 1.13
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica (2006) 1.13
The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab (2013) 1.12
Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals (2007) 1.12
Assessing quality obstetrical care: development of standardized measures. Jt Comm J Qual Patient Saf (2006) 1.12
Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med (2010) 1.11
Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol (2011) 1.10
Bone density assessment in patients with mucopolysaccharidosis: A preliminary report from patients with MPS II and VI. J Pediatr Rehabil Med (2010) 1.09
A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol (2012) 1.09
Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer (2005) 1.08
Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. J Natl Med Assoc (2006) 1.06
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther (2007) 1.06
Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med (2005) 1.05
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis (2011) 1.04
Initial outcomes from a 4-week follow-up study of the Text4baby program in the military women's population: randomized controlled trial. J Med Internet Res (2014) 1.03
A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol (2011) 1.02
Relationship of nutritional status to health and societal participation in children with cerebral palsy. J Pediatr (2002) 1.01
A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica (2010) 1.01
Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med (2008) 1.01
Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med (2009) 1.01
Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol (2005) 1.00
Iron metabolism and iron chelation in sickle cell disease. Acta Haematol (2009) 1.00
Hb E/beta-thalassaemia: a common & clinically diverse disorder. Indian J Med Res (2011) 1.00
Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med (2010) 0.99
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am J Med Genet A (2014) 0.98
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol (2013) 0.97
A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS). Am J Obstet Gynecol (2005) 0.97
Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood (2002) 0.96
Pharmacokinetics of sapropterin in patients with phenylketonuria. Clin Pharmacokinet (2008) 0.96
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis (2011) 0.95
Does liver biopsy overestimate liver iron concentration? Blood (2006) 0.95
HLA type and risk of alloimmunization in sickle cell disease. Am J Hematol (2009) 0.95
Orthopedic management of mucopolysaccharide disease. J Pediatr Rehabil Med (2010) 0.94
Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics (2003) 0.94
A simple and widely applicable method to 59Fe-radiolabel monodisperse superparamagnetic iron oxide nanoparticles for in vivo quantification studies. ACS Nano (2012) 0.93
Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol (2011) 0.93
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet (2003) 0.92
John M. Eisenberg Patient Safety and Quality Awards. Impact of CRM-based training on obstetric outcomes and clinicians' patient safety attitudes. Jt Comm J Qual Patient Saf (2007) 0.92
Erythrocytapheresis: Do Not Forget a Useful Therapy! Transfus Med Hemother (2008) 0.92
Using quality improvement strategies to enhance pediatric pain assessment. Int J Qual Health Care (2002) 0.92